Daily News logo Newsletter logo   Search News     Daily News   

Jury Verdict Against Novartis Pharmaceuticals For Retaliating Against Drug Sales Rep Who Took Maternity Leave

  Share With Friends

WASHINGTON, March 9 /PRNewswire/ -- On March 5, 2010, a jury in the United States District Court for the District of Columbia rendered a verdict in favor of pharmaceutical sales representative Mary Kate Breeden, awarding $289,669 against Novartis Pharmaceuticals Corporation on her claim of retaliation for taking maternity leave covered by the Family and Medical Leave Act (FMLA). Under the FMLA's liquidated damages provision, this amount is automatically doubled to $579,338. The District Court has yet to decide the amount front pay, attorney fees, and costs to award.

Mary Kate Breeden worked as a pharmaceutical sales representative for Novartis for over seven (7) years. After announcing that she was pregnant, Novartis cut her sales territory in half leaving her with fewer and smaller accounts. When she objected to the change, her supervisor said it was temporary and that she would be made "whole." Upon returning from maternity leave, Breeden was informed that the change was permanent. Novartis reorganized the sales territories again, at which time they consolidated Breeden's territory with another and eliminated her position. Novartis claimed that an outside consulting firm coordinated the original realignment and did not take Breeden's FMLA leave into account. However, Breeden's maternity leave was mentioned in a PowerPoint presentation that the consulting firm prepared about the realignment.

The jury found that Novartis retaliated against Ms. Breeden by cutting her sales territory when she announced that she was going to take leave and when Novartis refused to make her "whole" after she returned to work from FMLA leave, ultimately damaging her career and leading to her termination. Adam Augustine Carter, a Principal at The Employment Law GroupĀ® law firm (www.employmentlawgroup.com), a premier employment law firm based in D.C., stated, "The jury of 12 believed Ms. Breeden and disbelieved the executives of Novartis in arriving at this verdict. She was committed to her job, but her employer questioned her commitment. No employee should have to choose between having a family or keeping their job, and this jury verdict will help teach that lesson to all employers covered by the FMLA."

The Employment Law Group specializes in representing employees in whistleblower, wrongful termination, and discrimination cases. To contact them regarding questions or comments, call R. Scott Oswald or Adam Augustine Carter at 202-331-3911.

SOURCE The Employment Law Group, P.C.


 
Support Wikipedia


Follow NewsBlaze

on Twitter

@newsblaze


Find more stories recommended by Stumbleupon.

newsletter logo

What's Hot?
1 .Prosecution Paints a Portrait of Abuse in the Trial of George Huguely V! - 83
2 .Censorship in America - 57
3 .Texas: Cops Pull Over Drunk Cowgirl Wearing Only Cowboy Boots - 45
4 .Supermodel Bar Refaeli Adorns the Cover of the 2009 Sports Illustrated Swimsuit Issue on Newsstands Today! - 64
5 .Insitu Delivers Small Tactical Unmanned Aircraft Systems Capability to Marines - 46
6 .These 10 Comfortable Walking Shoes Are a Step in the Right Direction - 32
7 .Effective Costa Rica Marketing Ranks Country as Top Brand in Latin America - 32
8 .Early Marriage Has Harmful Effects on Women - 34
9 .IHOP Relies on Surging Bacon-Mania to Keep Pace With Competition - 30
10 .Christian Evangelist Father Johnson Reveals That India Embraces Christianity - 25
Updated: 21:59 PST     8567

NewsBlaze Editors

editors

NewsBlaze Writers


Writers Wanted

Help NewsBlaze provide daily news, including top stories, Home and Garden, Technology, The Environment and more. NewsBlaze Writer

Follow NewsBlaze

NewsBlaze Social Media Logos NewsBlaze Facebook NewsBlaze LinkedIn NewsBlaze Twitter NewsBlaze YouTube NewsBlaze MySpace
NewsBlaze 
Copyright © 2004-2012 NewsBlaze LLC
Use of this website is subject to our Terms of Service and Privacy Policy  | DMCA Notice |         Press Room